4 Cardiovascular Risk Reduction In addition to managing blood glucose levels and promoting weight loss, GLP-1 receptor agonists have been found to reduce the risk of cardiovascular events, which is a critical consideration in diabetic patients
This review begins with a summary of recent guidance on the use of GLP-1 RAs in patients with T2D followed by an overview of clinical considerations for use
Popular GLP-1 and related injection names include Wegovy, Ozempic, Saxenda, Mounjaro, and Zepbound
[6] Liraglutide (Victoza): 1.8 mg once daily for type 2 diabetes, and 3 mg once daily for chronic weight management (marketed as Saxenda)
In the liver, GCGR signaling stimulates hepatic glucose production through glycogenolysis and gluconeogenesis, promotes lipolysis, and inhibits fat accumulation
Hall, K